Abeona Therapeutics Inc vs Occidental Petroleum Corporation — how do they compare? Abeona Therapeutics Inc trades at $7.4 (market cap $424.33M), while Occidental Petroleum Corporation trades at $58.97 (market cap $55.89B). The key difference: Occidental Petroleum Corporation is far larger — about 131.7× Abeona Therapeutics Inc's market cap, and Occidental Petroleum Corporation pays a 2% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | OXY | |
|---|---|---|
Market Cap | $424.33M | $55.89B |
Sector | Health | Energy |
52-Week High | $7.45 | $66.24 |
52-Week Low | $4.17 | $38.92 |
Enterprise Value | $279.23M | $74.65B |
Dividend Yield | — | 2% |
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $7.24, up 4.93% today, with bullish technical signals from moving averages. The company shows exceptional profitability with 454.86% net income margin and 70.99% ROE, though revenue remains modest at $5.82M. Recent developments include CMS granting NTAP status for ZEVASKYN and expansion to seven treatment centers, while Q2 2026 earnings are scheduled for August 13, 2026.
Strong analyst support (66.7% buy ratings) and attractive valuation metrics (P/E 7.84, EV/EBITDA 3.8) support upside potential, but negative operating cash flow and shareholder investigation pose near-term risks. The stock's outlook depends on commercial execution and Q2 earnings results.
Occidental Petroleum (OXY) trades at $55.91, down 0.23% today, with a bullish technical outlook supported by moving averages and a consensus price target of $69.25. Recent Q2 2026 earnings of $2.40 per share beat expectations, driven by higher oil prices and strong cash flow, while the company focuses on debt reduction and targets over $4 billion in sustainable cash flow by 2030.
OXY presents a buy opportunity with solid profitability and growth prospects, but faces risks from oil price volatility and competitive pressures. Analysts are optimistic, with 50% recommending buy, though investors should monitor execution on cash flow targets and energy market fluctuations.
Trailing returns across standard periods
Latest headlines on both assets
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →Occidental Petroleum is an independent exploration and production company with operations in the United States, Latin America, and the Middle East. At the end of 2021, the company reported net proved reserves of 3.5 billion barrels of oil equivalent. Net production averaged 1,174 thousand barrels of oil equivalent per day in 2021 at a ratio of 75% oil and natural gas liquids and 25% natural gas.
Read more on OXY →